← Back to Home

Once-Weekly Insulin Extended to Children: FDA Approves Awiqli for Type 2 Diabetes in Patients Aged 10 and Older

Fewer basal insulin injections offer a new option for young patients. The approval is based on adult efficacy data, a pharmacokinetic study in 18 children and adolescents, and modeling estimates, while evidence on long-term use remains to be accumulated.

By SURL BioNews

For children who need basal insulin and their families, arranging daily injections is a recurring task in diabetes care. On October 23, the U.S. Food and Drug Administration (FDA) announced the approval of Awiqli (insulin icodec-abae) for patients aged 10 and older with type 2 diabetes, making it the first once-weekly insulin approved in the United States for this pediatric population and offering another treatment scheduling option.

Awiqli is a long-acting insulin analog developed by Novo Nordisk, administered as a once-weekly subcutaneous injection alongside diet and exercise to improve blood glucose control. The same drug was approved earlier this year for adults with type 2 diabetes. This expansion covers the pediatric type 2 diabetes indication; it does not cover type 1 diabetes, nor can it be extrapolated to children under 10.

The key basis for the approval was linking adult efficacy evidence with data on drug concentrations in children and adolescents. The FDA noted that pediatric participants absorbed the drug faster than adults after the first injection, but pharmacometric modeling estimated that blood concentrations would be similar to those in adults after the first few doses. On this basis, the regulator expects the drug to produce similar blood glucose-lowering effects in children and adolescents. This assessment did not come from a large, long-term efficacy trial in children.

The study, identified as NCT05790681, enrolled 18 patients aged 10 to under 18 at seven centers in the United States, with a mean age of 14.4 years. After participants received a single injection, the research team continued collecting blood samples through day 35 to observe changes in drug concentrations over time, then used modeling to estimate what would happen with repeated dosing once concentrations reached a steady state. This type of pharmacokinetic study primarily addresses how a drug is distributed and cleared within the body.

This is also where the limits of the evidence lie. The study did not assess pharmacodynamics—that is, the drug’s effects on physiological measures such as blood glucose. All participants were already using insulin and had obesity, so they cannot directly represent children and adolescents who have not yet received insulin treatment or who have other body types. The single-dose design also cannot directly answer whether long-term weekly injections can improve treatment persistence or blood glucose control.

Regarding safety, the study recorded six adverse events in two participants, all mild and resolved or recovered, as well as one episode of level 1 hypoglycemia. These short-term findings remain insufficient to rule out rare or long-term risks. The FDA cautioned that hypoglycemia is a common adverse reaction to insulin and can be life-threatening when severe. The different dosing schedule of a weekly formulation also makes dose identification, medication errors, and accidental overdose important aspects of care.

A once-weekly schedule could reduce the burden of basal insulin injections, but real-world use data are still needed to determine whether fewer injections translate into more consistent day-to-day treatment. This approval gives eligible children and adolescents a new option while highlighting a central task in pediatric drug evaluation: how to combine adult studies, data from children’s bodies, and modeling estimates while clearly acknowledging questions that have not yet been directly tested.

References

  1. U.S. Food and Drug Administration
  2. Novo Nordisk U.S.
  3. The American Journal of Managed Care
  4. Contemporary Pediatrics